Survival outcomes and influencing factors in Zhengzhou HIV/AIDS patients following antiretroviral therapy initiation (2014-2024): a retrospective cohort analysis

From 2014 to 2024, the overall survival of HIV-infected individuals receiving antiviral therapy in Zhengzhou was favorable. However, advanced age and a low baseline CD4⁺ T lymphocyte count were identified as significant factors for an elevated mortality risk. It is recommended to enhance clinical management for older patients and to initiate treatment early to improve CD4⁺ T lymphocyte levels, thereby further improving survival outcomes.